Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

Inclusion Criteria: * Male or female patients ≥ 18 years of age at the time of signing the informed consent document (not more than 10% of the patients can be \> 50 years of age). * Patient is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures. * Patient is able to adhere to the study visit schedule and other protocol requirements. * Patients who receive keloidectomy at Day 1/ Baseline only (Group 1): Patient has minimum of one keloid measuring ≥2 cm in length on earlobe or ≥3.0 cm in length on areas) other than earlobe, which has failed prior minimally invasive treatments for keloids including topicals and intralesional corticosteroid injections and that can be surgically resected at Day 1/ Baseline. * Patients who do not receive keloidectomy at Day 1/ Baseline only (Group 2): * Patient has a minimum of either one keloid measuring ≥3 cm in length, or multiple keloids, each measuring ≥1 cm in length , which failed prior minimally invasive treatments for keloids including topicals and intralesional corticosteroid injections. However, at least one keloid should not have been treated with surgery, cryotherapy, radiation, or any other procedure that leads to a deformity that interferes with proper clinical assessments. * Patient reports either Pain-NRS ≥4 , Itch-NRS ≥4, or DLQI ≥8both at Visit 1 (Screening) and Visit 2 (Baseline) * Patient is judged to be in otherwise good overall health as judg…